Meeting
2014 ASCO Annual Meeting
Quality of life and cognitive dysfunction in breast cancer survivors on a feasibility study of donepezil versus placebo.
Authors
Julia Lawrence
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC
Julia Lawrence , Leah Griffin , Steve Rapp , Michael J. Messino , Ernie P. Balcueva , Amarinthia E. Curtis , David L. Groteluschen , Thomas A. Samuel , Glenn Lesser , Doug Case , Edward G. Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Survivorship
Clinical Trial Registration Number
NCT01466270
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9516)
DOI
10.1200/jco.2014.32.15_suppl.9516
Abstract #
9516
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base REMEMBER trial (WF97116).
First Author: Alayna E Ernster
Poster
2024 ASCO Breakthrough
Exploring depression risk among breast cancer survivors: A nationwide cohort study in South Korea.
First Author: Hea Lim Choi
Poster
2023 ASCO Annual Meeting
Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.
First Author: Lorenzo Livi
Poster
2023 ASCO Annual Meeting
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
First Author: Kirin Saint